FDA gets tougher on hydrocodone in effort to battle abuse

|By:, SA News Editor

The FDA is set to reclassify hydrocodone-based painkillers as Schedule II substances (up from Schedule III) to reflect their potential for abuse.

What it means (practically speaking): Refills would be limited to a 90-day supply as opposed to 180 days.

Companies that make either brand name or generic versions: AbbVie (ABBV), Actavis (ACT), Teva (TEVA), Mallinckrodt (MNK).